<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta http-equiv="X-UA-Compatible" content="ie=edge">
  <title>Understanding The Effects of Matrix Parameters on Ex Vivo Preservation of Tumor Explants</title>
  <link rel="icon" href="./favicon.ico" type="image/x-icon">

  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/themes/light.css" />
  <script type="module"
    src="https://cdn.jsdelivr.net/npm/@shoelace-style/shoelace@2.16.0/cdn/shoelace-autoloader.js"></script>

  <link rel="stylesheet" href="./index.css">

  <link rel="stylesheet" href="./components/team-member/team-member.css">
  <script type="module" src="./components/team-member/team-member.js"></script>

  <link rel="stylesheet" href="./components/table-of-content/table-of-content.css">

  <script type="module" src="./components/image/image-component.js"></script>

  <script type="module" src="./components/video/video.js"></script>

  <link rel="stylesheet" href="./components/references/references.css">

  <link rel="stylesheet" href="./components/scroll-to-top/scroll-to-top.css">
  <script src="./components/scroll-to-top/scroll-to-top.js"></script>

  <script src="./components/table-component/table-component.js"></script>

  <link href="https://unpkg.com/gridjs/dist/theme/mermaid.min.css" rel="stylesheet" />
</head>

<body>
  <div class="content">
    <h1>Understanding The Effects of Matrix Parameters on Ex Vivo Preservation of Tumor Explants</h1>

    <!-- This is the team member component use to display details about your team members -->
    <div class="team-member-wrapper">
      <team-member avatar="assets/Profile.png" name="You Ruochii" department="Biomedical Engineering"
        year="2021"></team-member>
    </div>

    <!-- This is a divide from the shoelace library for aesthetic purpose -->
    <sl-divider></sl-divider>

    <!-- This is the table-of-content component use to define all of the link directly to each section -->
    <div class="table-of-content">
      <h2>Table of Contents</h2>
      <sl-tree>
        <sl-tree-item expanded>
          <a href="#section-header-1">1. Introduction</a>
        </sl-tree-item>

        <sl-tree-item expanded>
          <a href="#section-header-2">2. Literature Review</a>
          <sl-tree-item>
            <a href="#sub-section-2-header-1">2.1. Sub-section Header 1</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#sub-section-2-header-2">2.2. Sub-section Header 2</a>
          </sl-tree-item>

        </sl-tree-item>
        <sl-tree-item expanded>
          <a href="#section-header-3">3. Aims</a>
          <sl-tree-item>
            <a href="#sub-section-3-header-1">3.1. Hypotheses</a>
          </sl-tree-item>
          <sl-tree-item>
            <a href="#sub-section-3-header-2">3.2. Objectives</a>
          </sl-tree-item>
        </sl-tree-item>

        <sl-tree-item>
          <a href="#references">References</a>
        </sl-tree-item>
      </sl-tree>
    </div>
    <sl-divider></sl-divider>

    <div>

      <!-- This is an example of what a section might look like -->
      <div id="section-header-1">
        <h2> 1. Introduction </h2>
        <p>
          Cancer remains one of the deadliest diseases, 1 in 5 people develop cancer in their lifetime, 
          approximately 1 in 9 men and 1 in 12 women die from the disease [1]. 
          Chemotherapies and radiotherapies are the standard of care (SOC) for cancer treatment; 
          however, the traditional one-size-fits-all approach often results in treatment 
          noncompliance among a significant subgroup of patients. Many individuals also experience 
          severe side effects during or after treatment, including hair loss, skin damage, 
          fatigue, and gastrointestinal issues [2]. This clinical landscape underscores the urgent need for novel 
          strategies that can improve patient stratification, minimize side reactions and systemic toxicity, and enhance 
          patients’ overall well-being.
        </p>
        <p>
          Precision oncology is an emerging approach to cancer treatment that seeks to address 
          this unmet clinical need by tailoring treatments based on patients’ individual profiles. 
          A key component of precision oncology involves significant research efforts aimed at 
          developing novel therapies with cancer-targeting capability. Notable examples include 
          targeted therapies (HER-2, EGFR, VEGF inhibitors) and immunotherapies (PD-1/PD-L1/CTLA-4), 
          with many of them showing promising results in both in vitro and in vivo studies [3][4]. 
          However, the translation of these novel drug classes into clinical practice has been slow. 
          This delay can largely be attributed to the limitations of inappropriate preclinical models 
          used for drug screening and validation. Models like in vitro cell lines and xenografted 
          mice, although useful for exploring tumor biology in controlled environments, often lack the 
          predictive power needed to determine the most effective treatment strategies for individual patients [5]. Consequently, more than 90% of the biologics 
          shortlisted from these models fail to provide clinical benefits in trials [5].
        </p>
        <p>
          Advancements in our understanding of tumor biology have emphasized the critical role of 
          tumor heterogeneity—especially within the tumor microenvironment (TME)—in influencing 
          tumor responses to therapies [6]. Unfortunately, traditional reductionist models such as 
          cell lines and mouse models fail to accurately replicate the native TME. Therefore, 
          there is a pressing demand for cancer models that can effectively recapitulate the TME, 
          thereby improving drug assessment and facilitating the clinical translation of advanced 
          oncological strategies.
        </p>

        <image-component tag="image" source="assets/tme.png"
          subtitle="Figure 1: Components in TME and their functions [6]. "></image-component>
        <p>
          Patient-derived tumor explants (PDTE) emerge as superior materials for studying drug 
          responses and developing new cancer treatments for their ability to preserve key elements 
          of the native TME. Recent studies have demonstrated that PDTE maintains cell viability, 
          stromal composition, tissue architectural integrity, and cell-cell interactions [7]. Several 
          investigations among them further established the strong clinical correlations between 
          PDTE-derived drug responses and patient outcomes, showcasing the remarkable potential 
          of these ex vivo models in bridging preclinical findings to patient care [8][9][10].
        </p>
        <p>
          However, current ex vivo models still face limitations, notably their short lifespan 
          and the rapid degradation of structural and genetic features typically within 2 to 3 days [5]. 
          This short duration poses challenges for applications like cyclic drug testing, which 
          require longer timeframes for assessment—often on the order of weeks [11]. Additionally, for 
          treatments such as immunotherapies, which aim to reinvigorate immune cells’ cancer-killing 
          activity without direct cytotoxicity like chemotherapy, the time needed for therapeutic 
          effects is extended, likely exceeding the 3-day window [12]. Hence, extending the viability of 
          PDTE ex vivo is crucial for expanding its clinical applicability.
        </p>
        <p>
          In previous research conducted in our lab (currently under peer review), 
          we demonstrated that embedding peritoneal metastases (PM) PDTE in hyaluronic acid (HA) 
          hydrogels significantly extended survival to at least 8 days, outperforming traditional 
          methods such as PTFE inserts and Matrigel[5]. We also identified that hydrogel properties, 
          such as stiffness, are critical determinants of PM PDTE cultivation outcomes. This inspires 
          us to design and engineer a hydrogel with precisely tunable physicochemical properties, 
          which allows us to systemically dissect different characteristics and their roles in PDTE 
          preservation ex vivo. In doing so, we aim to enhance PDTE viability and survival to the 
          extent which would enable the developed ex vivo system to support clinical applications 
          otherwise unattainable with existing methods. Given the natural variability in tumors 
          across different histologies, we aspire to create a hydrogel-based ex vivo platform that 
          accommodates a wide range of cancers. For this proof-of-principle study, we selected HA 
          hydrogels due to their excellent performance in our prior investigations. We plan to achieve 
          tunability in these hydrogels by modifying HA molecules through the grafting of methacrylate (Me) 
          to their sidechains, employing an in-house-developed templating technology, and incorporating 
          degradable crosslinkers into the hydrogel formulation.
        </p>
          
      </div>

      <div id="sub-section-1-header-1">
        <h3>1.1 Sub-section Header 1</h3>
        <p>
          Ultrices dui sapien eget mi. Nunc mi ipsum faucibus vitae aliquet nec ullamcorper sit. Dolor purus non enim
          praesent elementum facilisis. Lacus vestibulum sed arcu non odio euismod lacinia at. Metus aliquam eleifend mi
          in nulla. Lacus sed viverra tellus in hac habitasse platea. Varius quam quisque id diam vel quam elementum
          pulvinar. Eleifend quam adipiscing vitae proin sagittis nisl rhoncus. Diam ut venenatis tellus in metus
          vulputate. Lorem ipsum dolor sit amet consectetur adipiscing elit pellentesque. Venenatis lectus magna
          fringilla
          urna. In nisl nisi scelerisque eu ultrices. Velit egestas dui id ornare arcu odio ut sem nulla. Quam id leo in
          vitae. Egestas congue quisque egestas diam in arcu cursus euismod quis. Porttitor leo a diam sollicitudin
          tempor
          id eu nisl.
        </p>
      </div>

      <div id="sub-section-1-header-2">
        <h3>1.2 Sub-section Header 2</h3>
        <p>
          Fermentum dui faucibus in ornare quam viverra orci. Donec ultrices tincidunt arcu non sodales. A diam maecenas
          sed enim ut sem viverra. Semper viverra nam libero justo laoreet sit. Mi sit amet mauris commodo quis. Auctor
          augue mauris augue neque gravida in fermentum et. Auctor elit sed vulputate mi sit amet. Maecenas pharetra
          convallis posuere morbi leo urna. Sem nulla pharetra diam sit amet nisl. Id nibh tortor id aliquet lectus.
          Nibh
          nisl condimentum id venenatis a condimentum vitae sapien. Convallis posuere morbi leo urna molestie at
          elementum.
        </p>

        <!-- This is an example of how you might use the image component -->
        <image-component tag="image" source="assets/requirement.png"
          subtitle="Image 1: iDP suggested pathway"></image-component>
      </div>
    </div>


    <br />
    <br />
    <sl-divider></sl-divider>
    <div>
      <div id="section-header-2">
        <h2>2. Section Header 2</h2>
        <p>
          Ornare arcu dui vivamus arcu felis bibendum ut tristique et. Mi proin sed libero enim sed faucibus turpis in
          eu. Odio ut sem nulla pharetra diam sit. Nibh cras pulvinar mattis nunc sed blandit libero. Lacus sed viverra
          tellus in hac habitasse platea dictumst vestibulum. At augue eget arcu dictum varius duis. Mauris ultrices
          eros in cursus turpis massa (Lindberg, 1967). Libero nunc consequat interdum varius sit amet mattis. Ut ornare
          lectus sit amet est placerat in egestas erat. Elementum curabitur vitae nunc sed. Proin nibh nisl condimentum
          id venenatis a condimentum vitae sapien (Chamberlin et al., 2008). Vitae tempus quam pellentesque nec nam
          aliquam sem.
        </p>
      </div>

      <div id="sub-section-2-header-1">
        <h3>2.1. Sub-section Header 1</h3>
        <p>
          Pellentesque nec nam aliquam sem et tortor consequat. Et netus et malesuada fames ac turpis egestas maecenas.
          Eu tincidunt tortor aliquam nulla facilisi. Nunc aliquet bibendum enim facilisis gravida. Elementum pulvinar
          etiam non quam lacus (Moll et al., 2011; Parker & Fox, 2010). Blandit cursus risus at ultrices mi. Arcu dui
          vivamus arcu felis bibendum ut tristique. Porttitor rhoncus dolor purus non enim praesent elementum facilisis.
          Mauris in aliquam sem fringilla. Non quam lacus suspendisse faucibus. Tristique senectus et netus et malesuada
          fames ac. <a href="#image">Link to the image above</a>
        </p>

        <!-- This is an example of how you might use the video component -->
        <video-component tag="rick" source="https://www.youtube.com/embed/dQw4w9WgXcQ"
          subtitle="Video: Never gonna give you up?"></video-component>
      </div>

      <div id="sub-section-2-header-2">
        <h3>2.2. Sub-section Header 2</h3>
        <p>
          Vitae proin sagittis nisl rhoncus mattis rhoncus urna neque viverra. Dignissim convallis aenean et tortor at
          risus viverra adipiscing. Facilisi nullam vehicula ipsum a arcu cursus. Adipiscing elit pellentesque
          habitant
          morbi tristique senectus et netus. Turpis massa tincidunt dui ut ornare lectus. Suspendisse sed nisi lacus
          sed. Diam volutpat commodo sed egestas egestas fringilla phasellus faucibus. Ut ornare lectus sit amet est
          placerat in egestas. Magna fringilla urna porttitor rhoncus. Imperdiet dui accumsan sit amet.
        </p>

        <!-- This is an example of how you might use the table component -->
        <table-component subtitle="Table: Demo table">
          <div id="table-1"></div>
        </table-component>
      </div>
    </div>

    <!-- This is an example of how you can use the references component to create references -->
    <div id="references" class="references">
      <sl-divider></sl-divider>
      <h2>References</h2>
      <ul>
        <li>
          [1] Lyon and  Geneva, “Global cancer burden growing, amidst mounting need for services,” 
          World Health Organization, 
          https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services 
          (accessed Oct. 31, 2024).
        </li>
        <li>
          [2] “Side effects of radiation therapy: Radiation effects on body,” Side Effects of 
          Radiation Therapy | Radiation Effects on Body | American Cancer Society, 
          https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/effects-on-different-parts-of-body.html#:~:text=The%20most%20common%20early%20side,or%20even%20years%20to%20develop 
          (accessed Oct. 27, 2024). 
        </li>
        <li>
          [3] K. Zhu et al., “Her2-targeted therapies in cancer: A systematic review - 
          biomarker research,” BioMed Central, 
          https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-024-00565-1 
          (accessed Nov. 2, 2024). 
        </li>
        <li>
          [4] K. K. W. To, W. Fong, and W. C. S. Cho, “Immunotherapy in treating EGFR-mutant 
          lung cancer: Current challenges and new strategies,” Frontiers in oncology, 
          https://pmc.ncbi.nlm.nih.gov/articles/PMC8185359/#:~:text=Combination%20of%20PD%2D1/PD%2DL1%20ICIs%20With%20Other%20Immunotherapies&text=Combination%20of%20CTLA%2D4%20and,%2DL1%20expression%20(138). 
          (accessed Nov. 2, 2024). 
        </li>
        <li>
          [5] K. Z. Wu, “Making in vitro tumor models whole again,” Advanced Healthcare Materials,
          https://onlinelibrary.wiley.com/doi/full/10.1002/adhm.202202279 
          (accessed Apr. 17, 2024)
        </li>
        <li>
          [6](https://link.springer.com/referenceworkentry/10.1007/978-3-030-80962-1_89-1) A.-D. Lazar, S. Dinescu, and M. Costache, “Tumor microenvironment complexity: 
          A pathological milieu that innately modulates cancer progression,” SpringerLink (accessed Oct. 27, 2024).
        </li>
        <li>
          [7] H. L. Kenerson, K. M. Sullivan, K. P. Labadie, V. G. Pillarisetty, and R. S. Yeung , 
          “Protocol for tissue slice cultures from human solid tumors to study therapeutic response
          ,” STAR Protocols, <a href = "https://www.sciencedirect.com/science/article/pii/S2666166721002811"><https://www.sciencedirect.com/science/article/pii/S2666166721002811></a>
          (accessed Oct. 27, 2024). 
        </li>
        <li>
          [8] E. Jun et al., “The identification of candidate effective combination regimens for 
          pancreatic cancer using the histoculture drug response assay,” Nature News, 
          https://www.nature.com/articles/s41598-020-68703-x#:~:text=The%20histoculture%20drug%20response%20assay%20(HDRA)%20is%20based%20on%20three,on%20inhibition%20of%20tumour%20viability 
          (accessed Oct. 27, 2024). 
        </li>
        <li>
          [9] R. A.  Vescio, K. M. Connors, T. Kubota, and R. M. Hoffman, 
          “Correlation of histology and drug response of human tumors grown in 
          native-state three-dimensional histoculture and in nude mice.,” PNAS, 
          https://www.pnas.org/doi/10.1073/pnas.2409983121 (accessed Oct. 27, 2024).
        </li>
        <li>
          [10] A. Yin, J. G. C. van Hasselt, H.-J. Guchelaar, L. E. Friberg, and D. J. A. R. 
          Moes, “Anti-cancer treatment schedule optimization based on tumor dynamics modelling 
          incorporating evolving resistance,” Nature News, 
          https://www.nature.com/articles/s41598-022-08012-7 (accessed Oct. 27, 2024). 
        </li>
        <li>
          [11] “Treatment cycles and courses of treatment,” Treatment for cancer | 
          Cancer Research UK, 
          https://www.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/how-you-have/treatment-cycles-and-courses 
          (accessed Nov. 3, 2024). 
        </li>
        <li>
          [12] J. Koury et al., “Immunotherapies: Exploiting the immune system for cancer treatment,” 
          Journal of immunology research, https://pmc.ncbi.nlm.nih.gov/articles/PMC5872614/ 
          (accessed Nov. 3, 2024). 
        </li>
      </ul>
    </div>
  </div>

  <!-- This is the code to display the scroll to top button for ergonomic -->
  <!-- You can leave it as it is, or if you don't like its aesthetics you can also just delete it, -->
  <!-- but it might reduce the user experience. -->
  <sl-button class="scroll-to-top" variant="primary" size="medium" circle onclick="scrollToTop()">
    <sl-icon name="arrow-up" label="Settings"></sl-icon>
  </sl-button>

  <script src="https://unpkg.com/gridjs/dist/gridjs.umd.js"></script>
  <script type="module" src="./components/table-component/table-component.js"></script>
</body>

</html>
